Table 3.
LC-MS drug-level quantification of patient with persistent viremia at time point of genotyping
| ID | ART | NNRTI | NRTI | PI | INI | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EFV | TDF | FTC | ATV | DRV 2*600 | DRV 1*800 | LPV | cobi | rtv | RAL | EVG | DTG | ||
| PV-01 | ABC, 3TC, DRV/r | – | – | – | – | – | 6370 | – | – | 1020 | – | – | – |
| PV-02 | FTC, TDF, DRV/r | – | 224 | 532 | – | 2100 | – | – | – | 1060 | – | – | – |
| PV-03 | TDF, FTC, ATV/r | – | 65.4 | 798 | 2900 | – | – | – | – | 1430 | – | – | – |
| PV-04 | TDF, FTC, DRV/r | – | 148 | 259 | – | – | 2580 | – | – | 185 | – | – | – |
| PV-05 | TDF, FTC, RAL | – | 94.4 | 1460 | – | – | – | – | – | – | 2600 | – | – |
| PV-06 | TDF, FTC, EVG | – | 279 | 1140 | – | – | – | – | 1810 | – | – | 1960 | – |
| PV-07 | TDF, FTV, EFV | 1070 | 65.4 | 201 | – | – | – | – | – | – | – | – | – |
| PV-08 | TDF, FTC, DRV/r | – | 63.8 | 203 | – | – | 4470 | – | – | 150 | – | – | – |
| PV-09 | TDF, FTC, DRV/r | – | 63.2 | 203 | – | – | 1980 | – | – | 286 | – | – | – |
| PV-10 | FTC, TDF, DRV/r | – | 271 | 890 | – | – | 6440 | – | – | 159 | – | – | – |
| PV-11 | TDF, FTC, EFV | 1260 | 75.1 | 202 | – | – | – | – | – | – | – | – | – |
| PV-12 | TDF, FTC, DRV/r | – | 127 | 1910 | – | – | 7360 | – | – | 513 | – | – | – |
| PV-13 | TDF, FTC, DRV/r | – | – | – | – | – | 687 | – | – | – | – | – | – |
| PV-14 | TDF, FTC, DRV/r | – | 191 | 1220 | – | – | 3750 | – | – | 308 | – | – | – |
| PV-16 | FTC, TDF, LPV/r | – | 52.2 | 66.7 | – | – | – | 257 | – | 25.2 | – | – | – |
| PV-17 | TDF, FTC, DRV/r | – | – | 69.9 | – | – | 986 | – | – | 14.7 | – | – | – |
| PV-18 | DRV/r, DTG | – | – | – | – | – | 1270 | – | – | 67,6 | – | – | 811 |
| PV-19 | TDF, FTC, DRV/r | – | 78.5 | 215 | – | – | 1950 | – | – | 151 | – | – | – |
| PV-20 | ABC, 3TC, DRV/r | – | – | – | – | – | 5320 | – | – | 578 | – | – | – |
| Control_1 | 3820 | 2500 | 1540 | 1500 | 1550 | 1550 | 3970 | 1510 | 2120 | 1670 | 1190 | 1950 | |
| Control_2 | 833 | 552 | 355 | 345 | 375 | 375 | 945 | 381 | 438 | 371 | 273 | 442 | |
| C min | 750 | 20 | 20 | 157 | 2430 | 841 | 1500 | 38 | 40 | 70 | 190 | 1110 | |
| C max | 5250 | 2500 | 2500 | 6340 | 6500 | 6060 | 14,000 | 1500 | 1230 | 2200 | 2090 | 4150 | |
Drug levels at time point of genotyping were quantified using HPLC/MS/MS as described in the method section. In addition, two internal controls (Control_1; Control_2) were used as references. Bold values indicate too low concentration of the indicated drug (<C min). DRV 1*800 indicates a dosing scheme of 800 mg darunavir once-daily, DRV2*600 refers to the dosing of 600 mg twice-daily. The C min and C max values are obtained from the patient information leaflets provided by the manufacturer. Regardless of the mode of ingestion, values for darunavir were available for twice-daily (DRV 2*600) only. All values are given in ng/ml